MDxHealth SA Share Price & Technical Analysis
MDXH · $0.79 (-1.25%)
Healthcare / Diagnostics & Research
$0.79
-1.25%
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to ass…
Price chart
Seasonality
May has 2 positive and 2 negative years (last 5 years shown)
-62% return in May, 12% avg return in past 3 year May month.
-113% return in 2026, 2% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -3% | -3% | -32% | -13% | -62% | – | – | – | – | – | – | – | -113% |
| 25 | -17% | -5% | -22% | 21% | 24% | 5% | 9% | 46% | 34% | 7% | -24% | -3% | 73% |
| 24 | 3% | -10% | -28% | -4% | 12% | -14% | 17% | 7% | -28% | -5% | -5% | 20% | -34% |
| 23 | 3% | -42% | -20% | 9% | 0% | -6% | 12% | -19% | -7% | -4% | 19% | 22% | -32% |
| 22 | -11% | -4% | -2% | -9% | -10% | 9% | -18% | 18% | -18% | 17% | -3% | -6% | -38% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Oversold
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. It offers genomic prostate score, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. The company sells its products through urology sales force consisting of direct sales representatives, strategic account managers, and regional sales managers. The company has a collaboration the initiation of Genomic Prostate Score (GPS) testing. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$99.13M
P/E ratio
—
52W high
$5.33
52W low
$0.68
Volume
13,17,901
Beta
-510468.06
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is MDxHealth SA share price today?
- MDxHealth SA (MDXH) last traded around $0.79 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does MDXH have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for MDXH. Download the app for real-time alerts.
- How can I analyze MDxHealth SA stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.